Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    September 2019
  1. ROBERTS AL, Huang T, Koenen KC, Kim Y, et al
    Posttraumatic stress disorder (PTSD) is associated with increased risk of ovarian cancer: a prospective and retrospective longitudinal cohort study.
    Cancer Res. 2019 Sep 5. pii: 0008-5472.CAN-19-1222.
    PubMed     Text format     Abstract available


    August 2019
  2. PERES LC, Mallen AR, Townsend MK, Poole EM, et al
    High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the Ovarian Cancer Cohort Consortium.
    Cancer Res. 2019 Aug 28. pii: 0008-5472.CAN-19-1554.
    PubMed     Text format     Abstract available


    July 2019
  3. SHANG S, Yang J, Jazaeri AA, Duval AJ, et al
    Chemotherapy-induced distal enhancers drive transcriptional program to maintain the chemoresistant state in ovarian cancer.
    Cancer Res. 2019 Jul 29. pii: 0008-5472.CAN-19-0215.
    PubMed     Text format     Abstract available


  4. FUKUMOTO T, Fatkhutdinov N, Zundell JA, Tcyganov EN, et al
    HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
    Cancer Res. 2019 Jul 16. pii: 0008-5472.CAN-19-1302.
    PubMed     Text format     Abstract available


  5. TESFAY L, Paul BT, Konstorum A, Deng Z, et al
    Steroyl-CoA Desaturase 1 (SCD1) protects ovarian cancer cells from ferroptotic cell death.
    Cancer Res. 2019 Jul 3. pii: 0008-5472.CAN-19-0369.
    PubMed     Text format     Abstract available


    May 2019
  6. MUYS BR, Sousa JF, Placa JR, Araujo LF, et al
    miR-450a acts as a tumor suppressor in ovarian cancer by regulating energy metabolism.
    Cancer Res. 2019 May 17. pii: 0008-5472.CAN-19-0490.
    PubMed     Text format     Abstract available


  7. DORAYAPPAN KDP, Gardner ML, Hisey CL, Zingarelli RA, et al
    A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer.
    Cancer Res. 2019 May 16. pii: 0008-5472.CAN-18-3538.
    PubMed     Text format     Abstract available


  8. TRAVERS M, Brown SM, Dunworth M, Holbert CE, et al
    DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer.
    Cancer Res. 2019 May 14. pii: 0008-5472.CAN-18-4018.
    PubMed     Text format     Abstract available


  9. MUKHERJEE A, Huynh V, Gaines K, Reh WA, et al
    Targeting the High Mobility Group Box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin.
    Cancer Res. 2019 May 6. pii: 0008-5472.CAN-19-0542.
    PubMed     Text format     Abstract available


    March 2019
  10. SRIVASTAVA AK, Banerjee A, Cui T, Han C, et al
    Inhibition of miR-328-3p impairs cancer stem cell function and prevents metastasis in ovarian cancer.
    Cancer Res. 2019 Mar 20. pii: 0008-5472.CAN-18-3668.
    PubMed     Text format     Abstract available


  11. NATARAJAN S, Foreman KM, Soriano MI, Rossen NS, et al
    Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis.
    Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2616.
    PubMed     Text format     Abstract available


    February 2019
  12. CHOI J, Brown KM
    A Dynamic Cis-Regulation Pattern Underlying Epithelial Ovarian Cancer Susceptibility.
    Cancer Res. 2019;79:439-440.
    PubMed     Text format     Abstract available


    December 2018
  13. HOODA J, Novak M, Salomon MP, Matsuba C, et al
    Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer.
    Cancer Res. 2018 Dec 18. pii: 0008-5472.CAN-18-2297.
    PubMed     Text format     Abstract available


  14. YANG Y, Wu L, Shu X, Lu Y, et al
    Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk.
    Cancer Res. 2018 Dec 17. pii: 0008-5472.CAN-18-2726.
    PubMed     Text format     Abstract available


    November 2018
  15. BUCKLEY MA, Woods NT, Tyrer JP, Mendoza-Fandino G, et al
    Functional analysis and fine mapping of the 9p22.2 ovarian cancer susceptibility locus.
    Cancer Res. 2018 Nov 28. pii: 0008-5472.CAN-17-3864.
    PubMed     Text format     Abstract available


    October 2018

  16. Correction: RSF1 Is a Positive Regulator of NFkappaB-induced Gene Expression Required for Ovarian Cancer Chemoresistance.
    Cancer Res. 2018;78:6024.
    PubMed     Text format    


    September 2018
  17. LIU M, Thomas SL, DeWitt AK, Zhou W, et al
    Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells.
    Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-17-3953.
    PubMed     Text format     Abstract available


    August 2018
  18. BYEON Y, Lee JW, Choi WS, Won JE, et al
    CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer.
    Cancer Res. 2018 Aug 16. pii: 0008-5472.CAN-17-3871.
    PubMed     Text format     Abstract available



  19. Correction: Significance of MAD2 Expression to Mitotic Checkpoint Control in Ovarian Cancer Cells.
    Cancer Res. 2018;78:4800.
    PubMed     Text format    


  20. BELANGER F, Fortier E, Dube M, Lemay JF, et al
    Replication Protein A Availability During DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-18-0618.
    PubMed     Text format     Abstract available


    July 2018
  21. LU Y, Beeghly-Fadiel A, Wu L, Guo X, et al
    A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk.
    Cancer Res. 2018 Jul 27. pii: 0008-5472.CAN-18-0951.
    PubMed     Text format     Abstract available



  22. Correction: Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer.
    Cancer Res. 2018;78:4099.
    PubMed     Text format    



  23. Correction: FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.
    Cancer Res. 2018;78:3742.
    PubMed     Text format    


    June 2018

  24. Correction: Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
    Cancer Res. 2018;78:3402.
    PubMed     Text format    


  25. HIRST J, Pathak HB, Hyter S, Pessetto ZY, et al
    Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-3993.
    PubMed     Text format     Abstract available


    May 2018
  26. HAUTANIEMI S, Kozlowska E, Farkkila A, Vallius T, et al
    Mathematical modeling predicts response to chemotherapy and drug combinations in ovarian cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3746.
    PubMed     Text format     Abstract available


  27. SALEM M, O'Brien JA, Bernaudo S, Shawer H, et al
    miRNA-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway.
    Cancer Res. 2018 May 10. pii: 0008-5472.CAN-17-3014.
    PubMed     Text format     Abstract available


  28. CARROLL MJ, Fogg KC, Patel HA, Krause HB, et al
    Alternatively activated macrophages upregulate mesothelial expression of P-selectin to enhance adhesion of ovarian cancer cells.
    Cancer Res. 2018 May 8. pii: 0008-5472.CAN-17-3341.
    PubMed     Text format     Abstract available


  29. LUO XL, Deng C, Su XD, Wang F, et al
    Loss of MED12 induces tumor dormancy in human epithelial ovarian cancer via downregulation of EGFR.
    Cancer Res. 2018 May 7. pii: 0008-5472.CAN-18-0134.
    PubMed     Text format     Abstract available


    April 2018
  30. SHARMA SK, Chow A, Monette S, Vivier D, et al
    Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
    Cancer Res. 2018;78:1820-1832.
    PubMed     Text format     Abstract available


  31. SAINI U, Suarez AA, Naidu S, Wallbillich JJ, et al
    STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.
    Cancer Res. 2018;78:1739-1750.
    PubMed     Text format     Abstract available


    March 2018
  32. CONDELLO S, Sima LE, Ivan C, Cardenas H, et al
    Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche.
    Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-17-2319.
    PubMed     Text format     Abstract available


    January 2018
  33. HA JH, Radhakrishnan R, Jayaraman M, Yan M, et al
    Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.
    Cancer Res. 2018 Jan 31. pii: 0008-5472.CAN-17-1624.
    PubMed     Text format     Abstract available


  34. ZHANG Y, Li L, Wang L, Li J, et al
    Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer.
    Cancer Res. 2018 Jan 26. pii: 0008-5472.CAN-17-2460.
    PubMed     Text format     Abstract available


  35. CURRY E, Zeller C, Masrour N, Patten D, et al
    Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-1650.
    PubMed     Text format     Abstract available


  36. LU Y, Hu Z, Mangala LS, Stine ZE, et al
    MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
    Cancer Res. 2018;78:64-74.
    PubMed     Text format     Abstract available


    December 2017
  37. KANG J, Shin SH, Yoon H, Huh J, et al
    FIH is an oxygen sensor in ovarian cancer for G9a/GLP-driven epigenetic regulation of metastasis-related genes.
    Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-2506.
    PubMed     Text format     Abstract available


  38. FANG F, Cardenas H, Huang H, Jiang G, et al
    Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Re-sensitization to Platinum Drugs.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1492.
    PubMed     Text format     Abstract available


    November 2017
  39. HIRAMATSU K, Serada S, Enomoto T, Takahashi Y, et al
    LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0910.
    PubMed     Text format     Abstract available


    October 2017
  40. HOUSE CD, Jordan E, Hernandez L, Ozaki M, et al
    NF-kB promotes ovarian tumorigenesis via classical pathways supporting proliferative cancer cells and alternative pathways supporting ALDH+ cancer stem-like cells.
    Cancer Res. 2017 Oct 26. pii: canres.0366.2017.
    PubMed     Text format     Abstract available


  41. CICHOCKI F, Valamehr B, Bjordahl R, Zhang B, et al
    GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
    Cancer Res. 2017;77:5664-5675.
    PubMed     Text format     Abstract available


  42. LAMICHHANE P, Karyampudi L, Shreeder B, Krempski J, et al
    IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer.
    Cancer Res. 2017 Oct 9. pii: canres.0740.2017.
    PubMed     Text format     Abstract available


  43. GALL VA, Philips AV, Qiao N, Clise-Dwyer K, et al
    Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
    Cancer Res. 2017;77:5374-5383.
    PubMed     Text format     Abstract available


    September 2017
  44. YIN X, Jing Y, Cai MC, Ma P, et al
    Clonality, heterogeneity and evolution of synchronous bilateral ovarian cancer.
    Cancer Res. 2017 Sep 28. pii: canres.1461.2017.
    PubMed     Text format     Abstract available


  45. FALCETTA F, Bizzaro F, D'Agostini E, Bani MR, et al
    Modeling cytostatic and cytotoxic responses to new treatment regimens for ovarian cancer.
    Cancer Res. 2017 Sep 26. pii: canres.1099.2017.
    PubMed     Text format     Abstract available


    July 2017
  46. ZHU W, Jarman KE, Lokman NA, Neubauer HA, et al
    CIB2 negatively regulates oncogenic signaling in ovarian cancer via sphingosine kinase 1.
    Cancer Res. 2017 Jul 20. pii: canres.0025.2017.
    PubMed     Text format     Abstract available


  47. PIACENTE F, Caffa I, Ravera S, Sociali G, et al
    Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Cancer Res. 2017;77:3857-3869.
    PubMed     Text format     Abstract available


  48. YANG D, Sun B, Zhang X, Cheng D, et al
    Huwe1 sustains normal ovarian epithelial cell transformation and tumor growth through the histone H1.3-H19 cascade.
    Cancer Res. 2017 Jul 7. pii: canres.2597.2016.
    PubMed     Text format     Abstract available


    June 2017
  49. MARCHAN R, Buttner B, Lambert J, Edlund K, et al
    Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinoma.
    Cancer Res. 2017 Jun 26. pii: canres.2065.2016.
    PubMed     Text format     Abstract available


  50. ETEMADMOGHADAM D, Azar WJ, Lei Y, Moujaber T, et al
    EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas.
    Cancer Res. 2017 Jun 23. pii: canres.2224.2016.
    PubMed     Text format     Abstract available


  51. RIVERA B, Di Iorio M, Frankum J, Nadaf J, et al
    Functionally null RAD51D missense mutation associates strongly with ovarian carcinoma.
    Cancer Res. 2017 Jun 23. pii: canres.0190.2017.
    PubMed     Text format     Abstract available


    May 2017

  52. Correction: Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
    Cancer Res. 2017;77:2770.
    PubMed     Text format    


    April 2017
  53. SANS M, Gharpure KM, Tibshirani R, Zhang J, et al
    Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
    Cancer Res. 2017 Apr 17. pii: canres.3044.2016.
    PubMed     Text format     Abstract available



  54. Correction: EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells.
    Cancer Res. 2017;77:2175.
    PubMed     Text format    


  55. WANG L, Shi C, Wright FA, Guo D, et al
    Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment.
    Cancer Res. 2017 Apr 10. pii: canres.3119.2016.
    PubMed     Text format     Abstract available


  56. OSE J, Poole EM, Schock H, Lehtinen M, et al
    Androgens are differentially associated with ovarian cancer subtypes in the Ovarian Cancer Cohort Consortium.
    Cancer Res. 2017 Apr 5. pii: canres.3322.2016.
    PubMed     Text format     Abstract available


    March 2017
  57. JOSEPHS DH, Bax HJ, Dodev T, Georgouli M, et al
    Anti-Folate Receptor-alpha IgE but not IgG Recruits Macrophages to Attack Tumors via TNFalpha/MCP-1 Signaling.
    Cancer Res. 2017;77:1127-1141.
    PubMed     Text format     Abstract available


    February 2017
  58. CHEN MW, Yang ST, Chien MH, Hua KT, et al
    The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer.
    Cancer Res. 2017 Feb 16. pii: canres.1115.2016.
    PubMed     Text format     Abstract available


  59. SUNDARAM KM, Zhang Y, Mitra AK, Kouadio JK, et al
    Prolactin receptor-mediated internalization of imaging agents detects epithelial ovarian cancer with enhanced sensitivity and specificity.
    Cancer Res. 2017 Feb 15. pii: canres.1454.2016.
    PubMed     Text format     Abstract available


  60. JUNG M, Russell AJ, Liu B, George J, et al
    A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.
    Cancer Res. 2017;77:971-981.
    PubMed     Text format     Abstract available


    January 2017
  61. ZHAO L, Ji G, Le X, Wang C, et al
    Long non-coding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer.
    Cancer Res. 2017 Jan 13. pii: canres.1615.2016.
    PubMed     Text format     Abstract available


    November 2016
  62. BAI S, Ingram P, Chen YC, Deng N, et al
    EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells.
    Cancer Res. 2016;76:6396-6409.
    PubMed     Text format     Abstract available


  63. YOKOYAMA Y, Zhu H, Lee JH, Kossenkov AV, et al
    BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.
    Cancer Res. 2016;76:6320-6330.
    PubMed     Text format     Abstract available


  64. IORIO MV, Croce CM
    Commentary on microRNA Fingerprint in Human Epithelial Ovarian Cancer.
    Cancer Res. 2016;76:6143-6145.
    PubMed     Text format    


    October 2016
  65. KANLIKILICER P, Saber M, Bayraktar R, Mitra R, et al
    Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells.
    Cancer Res. 2016 Oct 14. pii: canres.0714.2016.
    PubMed     Text format     Abstract available


    September 2016
  66. CLARK CA, Gupta H, Sareddy GR, Pandeswara S, et al
    Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma.
    Cancer Res. 2016 Sep 26. pii: canres.0258.2016.
    PubMed     Text format     Abstract available


    August 2016
  67. WALTON J, Blagih J, Ennis D, Leung E, et al
    CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma.
    Cancer Res. 2016 Aug 16. pii: canres.1272.2016.
    PubMed     Text format     Abstract available


    May 2016
  68. SCHULTZ MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, et al
    The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype.
    Cancer Res. 2016 May 23. pii: canres.2834.2015.
    PubMed     Text format     Abstract available


  69. KIM SY, Ebbert K, Cordeiro MH, Romero MM, et al
    Constitutive activation of PI3K in oocytes induces ovarian granulosa cell tumors.
    Cancer Res. 2016 May 9. pii: canres.3358.2015.
    PubMed     Text format     Abstract available


    April 2016
  70. FEHRINGER G, Kraft P, Pharoah PD, Eeles RA, et al
    Cross-cancer genome-wide analysis of lung, ovary, breast, prostate and colorectal cancer reveals novel pleiotropic associations.
    Cancer Res. 2016 Apr 20. pii: canres.2980.2015.
    PubMed     Text format     Abstract available


    January 2016
  71. POPOVA T, Manie E, Boeva V, Battistella A, et al
    Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications.
    Cancer Res. 2016 Jan 19. pii: canres.2128.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: